Difference between revisions of "File:Fig1 Li JofPharmAnal2020 10-2.jpg"
Shawndouglas (talk | contribs) |
Shawndouglas (talk | contribs) (Added summary.) |
||
| Line 1: | Line 1: | ||
==Summary== | |||
{{Information | |||
|Description='''Graphical abstract''' Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence of SARS-CoV-2 has been marked as the third introduction of a highly pathogenic coronavirus into the human population after the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) in the twenty-first century. In this minireview, we provide a brief introduction of the general features of SARS-CoV-2 and discuss current knowledge of molecular immune pathogenesis, diagnosis and treatment of COVID-19 on the base of the present understanding of SARS-CoV and MERS-CoV infections, which may be helpful in offering novel insights and potential therapeutic targets for combating the SARS-CoV-2 infection. | |||
|Source={{cite journal |title=Molecular immune pathogenesis and diagnosis of COVID-19 |journal=Journal of Pharmaceutical Analysis |author=Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. |volume=10 |issue=2 |pages=102–8 |year=2020 |doi=10.1016/j.jpha.2020.03.001}} | |||
|Author=Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. | |||
|Date=2020 | |||
|Permission=[https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International] | |||
}} | |||
== Licensing == | == Licensing == | ||
{{cc-by-nc-nd-4.0}} | {{cc-by-nc-nd-4.0}} | ||
Latest revision as of 16:27, 1 May 2020
Summary
| Description |
Graphical abstract Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence of SARS-CoV-2 has been marked as the third introduction of a highly pathogenic coronavirus into the human population after the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) in the twenty-first century. In this minireview, we provide a brief introduction of the general features of SARS-CoV-2 and discuss current knowledge of molecular immune pathogenesis, diagnosis and treatment of COVID-19 on the base of the present understanding of SARS-CoV and MERS-CoV infections, which may be helpful in offering novel insights and potential therapeutic targets for combating the SARS-CoV-2 infection. |
|---|---|
| Source |
Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. (2020). "Molecular immune pathogenesis and diagnosis of COVID-19". Journal of Pharmaceutical Analysis 10 (2): 102–8. doi:10.1016/j.jpha.2020.03.001. |
| Date |
2020 |
| Author |
Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. |
| Permission (Reusing this file) |
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International |
| Other versions |
Licensing
  |
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
File history
Click on a date/time to view the file as it appeared at that time.
| Date/Time | Thumbnail | Dimensions | User | Comment | |
|---|---|---|---|---|---|
| current | 16:22, 1 May 2020 |  | 1,179 × 886 (325 KB) | Shawndouglas (talk | contribs) |
You cannot overwrite this file.
File usage
The following 4 pages use this file:
- Template:COVID-19 Testing, Reporting, and Information Management in the Laboratory/Overview of COVID-19 and its challenges/Challenges of managing the disease in the human population
- Template:Overview of COVID-19 and its challenges
- LII:COVID-19 Testing, Reporting, and Information Management in the Laboratory/Overview of COVID-19 and its challenges
- Book:COVID-19 Testing, Reporting, and Information Management in the Laboratory/Overview of COVID-19 and its challenges/Challenges of managing the disease in the human population
